Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

156.15 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
Exposures Product Safety
Johnson & Johnson's stock price is at a critical turning point
Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
3 personal care stocks that smell like good earnings plays
Management remarks about how they plan to use technology to drive growth could matter just as much as near-term financials for these personal care companies. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
US Stocks Prepare For Nervy Start Ahead of Netflix, TI Earnings: Analyst Says Cash Waiting On Sidelines Could Flood Street If This Happens
The mood turned circumspect on Tuesday as traders digested a deluge of earnings reports and anticipated market-moving economic data for the week. 
Via Benzinga
How Is The Market Feeling About Johnson & Johnson?
Via Benzinga
Johnson & Johnson Surpasses $2.28 EPS Expectation in Q4
Johnson & Johnson exceeded the anticipated earnings per share (EPS) of $2.28, showcasing operational efficiency and resilience in a complex global business environment. 
Via Talk Markets
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
From Johnson & Johnson
Via Business Wire
2 Genius Safe Stocks to Buy for 2024 and Beyond
These companies have considerable profits and tried-and-true dividends in common. 
Via The Motley Fool
Fear & Greed Index Remains In 'Greed' Zone; Dow Settles Above 38,000
The CNN Money Fear and Greed index remained in the "Greed" zone on Monday. U.S. stocks closed higher on Monday, with the Dow Jones index settling above the 38,000 mark for the first time. 
Via Benzinga
Topics Stocks
Exposures US Equities
Verizon, Netflix And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
3 Dividend Stocks For A Steady Drip Of Income
Dividend Reinvestment Plans allow investors to unleash the power of compounding dividends. 
Via Talk Markets
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Earnings Scheduled For January 23, 2024
Companies Reporting Before The Bell • Webster Finl (NYSE:WBS) is estimated to report quarterly earnings at $1.46 per share on revenue of $603.11 million. 
Via Benzinga
Dow Jones Stocks: From 3M To Intel, A Big Earnings Week For Blue Chips
Eight Dow Jones stock report earnings this week. Several, including Verizon and 3M, are in buy zones or near buy points. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday?
US stocks rise to record highs on strong earnings reports, with small caps outperforming. Dollar steady, gold down, oil up. Bitcoin tumbles. AMD, TSLA, ADM, GILD, WDC top movers. GE, AAPL, FB, AMZN,... 
Via Benzinga
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval
FDA-approved Balversa for urothelial carcinoma treatment. The first oral FGFR kinase inhibitor offers clinical benefits, extended overall survival, and a breakthrough for FGFR alterations in metastatic... 
Via Benzinga
Exposures Product Safety
Johnson & Johnson's Q4 Earnings: Spotlight On Dividend Security Following Kenvue Split, Legal Costs, Acquisitions
Johnson & Johnson (JNJ) to report Q4 earnings on Jan. 23, with expectations of $2.28 EPS and $20.99B revenue. Strong, diverse company with reliable dividend, but impacted by talc lawsuit settlement and... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 undervalued stocks: Is now the right time to buy?
WK Kellogg, Newmont, and WEC Energy Group have upside potential as undervalued stocks, although each is navigating challenges that pushed valuations lower. 
Via MarketBeat
I'm Putting My Cash Stockpile to Work on These 3 Stocks
With the market selling off to start the year, this Fool plans to put some of his growing cash pile to work. 
Via The Motley Fool
Tesla, Netflix, Intel Take Center Stage In Pivotal Q4 Earnings Week As S&P 500 Eyes Breaking New Highs
According to Factset, the fourth-quarter earnings season has had a weak start, with the percentage of S&P 500 companies reporting positive earnings surprises below average. 
Via Benzinga
Topics Stocks
Exposures US Equities
Nearing Retirement? These Stocks Are as Safe as They Come
These stocks should provide solid income with little drama. 
Via The Motley Fool
Walgreens Boots Alliance Just Cut Its Dividend: Here Are 2 Companies That Won't
Not every dividend stock is created equal, and these two far exceed Walgreens Boots Alliance. 
Via The Motley Fool
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024
These stocks may help you win in 2024 -- no matter what the market does. 
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More in 2024
These big winners could keep the momentum going. 
Via The Motley Fool
Q4 Earnings Results Reflect Stability
We get into the heart of the Q4 earnings season this week, with more than 225 companies reporting results, including 71 S&P 500 members from various sectors and industries 
Via Talk Markets
Topics Stocks
Exposures US Equities
3 Reasons to Rely on Dividend Stocks
Dividend stocks can be a great hedge against volatile while still providing powerful returns via compounding. 
Via InvestorPlace
7 Must-Have Stocks for Serious Wealth Accumulation
Unlock the strategies of seven finance and commerce stalwarts on the path to serious wealth accumulation and industry leadership. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
The 3 Most Undervalued Value Stocks to Buy in January
With so many investments turning in a surprisingly robust performance last year, it’s time to consider undervalued value stocks. 
Via InvestorPlace
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.